AVITA MED LTD/S (NASDAQ:RCEL) Sets New 52-Week High at $9.80

AVITA MED LTD/S ADR (NASDAQ:RCEL) shares reached a new 52-week high during trading on Friday . The company traded as high as $9.80 and last traded at $9.80, with a volume of 2326 shares changing hands. The stock had previously closed at $9.60.

A number of analysts recently commented on RCEL shares. ValuEngine lowered AVITA MED LTD/S from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Lake Street Capital increased their price objective on AVITA MED LTD/S from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, October 31st.

The firm has a market capitalization of $778.29 million, a PE ratio of -25.08 and a beta of 1.28.

AVITA MED LTD/S Company Profile (NASDAQ:RCEL)

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.

Featured Story: Bid-Ask Spread

Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.